Matthew K. Fust - Jul 26, 2021 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Jul 26, 2021
Transactions value $
-$88,400
Form type
4
Date filed
7/27/2021, 08:00 PM
Previous filing
Jul 20, 2021
Next filing
Sep 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $9.55K +5K +39.89% $1.91* 17.5K Jul 26, 2021 Direct F1
transaction CRNX Common Stock Sale -$98K -5K -28.51% $19.59 12.5K Jul 26, 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Non-qualified stock option (Right to Buy) Options Exercise $0 -5K -15.58% $0.00 27.1K Jul 26, 2021 Common stock 5K $1.91 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2 Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.
F3 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $19.59. The range of sales prices on the transaction date was $19.53 to $20.00 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.